Stockscreener 앱 받기
41.95
1.55%
-0.66
시간 외 거래:
41.95
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMFI Overbought - dars.gov.et
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued? - Sahm
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside - TradingView
Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock - MarketBeat
CLDX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million - Bitget
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex: Q2 Earnings Snapshot - Barchart.com
Celldex Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M - marketscreener.com
Celldex Reports Second Quarter Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary - TradingView
Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M - Stock Titan
Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celldex reports Q2 net loss of $73.5M; cash and marketable securities $717.6M at June 30, 2026 - TradingView
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week HighTime to Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com - Investing.com South Africa
Celldex Therapeutics stock hits 52-week high at $40.30 - Investing.com
Celldex Therapeutics earnings up next as Phase III data looms - Investing.com
Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsight - The Manila Times
CLDX Q2'26 Earnings: EPS estimate is (1.06) USD - TradingView
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Biotechnology Innovator with 51% Potential Upside - DirectorsTalk Interviews
Celldex Therapeutics, Inc. $CLDX Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
29,300 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Seven Fleet Capital Management LP - MarketBeat
CLDX Q2'26 Earnings: revenue estimate is 734.92K USD - TradingView
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - MarketBeat
Eversept Partners LP Has $56.72 Million Stock Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380 - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celldex Therapeutics Inc (CLDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celldex Therapeutics, Inc. $CLDX is Commodore Capital LP's 7th Largest Position - MarketBeat
TradingKey - TradingKey
Celldex Therapeutics Inc (CLDX) Balance Sheet - TradingKey
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX) - Seeking Alpha
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2 - TradingView
CLDX|Celldex Therapeutics Inc|Price:35.280|Chg%:-0.140 - TradingKey
Are Phase 2 Prurigo Nodularis Data And CFO Transition Altering The Investment Case For Celldex (CLDX)? - Sahm
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run - Sahm
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70 - Moomoo
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF) - The Globe and Mail
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78 - webull.com
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial DiscontinuationSlideshow (NASDAQ:CLDX) 2026-07-22 - Seeking Alpha
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study - BioPharma Dive
0.52%
0.07%
자본화:
|
볼륨(24시간):